Product information and disease description Place of product in therapy Disease description Epidemiology

Prevalence of Second-line advanced biliary tract cancer

4 evidence topics · 5 sources

Summary: prevalence of biliary tract cancer and the size of the second-line pool

Prevalence of biliary tract cancer is low relative to incidence because survival is short. SEER estimated 116,514 people living with liver and intrahepatic bile duct cancer in the United States in 2023, and the lifetime risk of a diagnosis of liver and intrahepatic bile duct cancer is approximately 1.1 percent. A SEER analysis of 40,030 cholangiocarcinoma cases reported a 16-year limited-duration prevalence for cholangiocarcinoma of 5.92, higher for extrahepatic (4.23) than intrahepatic (1.69) disease, with the intrahepatic figure rising across successive periods from 0.60 in 2001 to 2006 to 1.37 in 2013 to 2017.

The prevalent second-line population is smaller still, because median overall survival from second-line randomization was 6.2 months with FOLFOX and 5.3 months with active symptom control alone in ABC-06. Approximately 60% of participants with advanced biliary tract cancer have no targetable alteration and are therefore candidates for non-targeted second-line therapy; the manufacturer places the share with targeted mutations at approximately 15% to 20%.

Prevalence: people living with liver and intrahepatic bile duct cancer in the United States

“In 2023, there were an estimated 116,514 people living with liver and intrahepatic bile duct cancer in the United States.” (opens the source at this quote in a new tab)
“Approximately 1.1 percent of men and women will be diagnosed with liver and intrahepatic bile duct cancer at some point during their lifetime, based on 2021–2023 data.” (opens the source at this quote in a new tab)

Prevalence: limited-duration prevalence of cholangiocarcinoma in SEER, 2001 to 2017

“From 2001 to 2017, the LDP of CCA was 5.92% (Table 3) and was higher for eCCA vs iCCA (4.23% vs 1.69%). The LDP of iCCA increased from 2001-2006 (0.60%) to 2007-2012 (0.98%) to 2013-2017 (1.37%), whereas the LDP for eCCA remained relatively stable.” (opens the source at this quote in a new tab)
“LDP is defined as the number of people alive on a certain day who had a diagnosis of the disease within the past 16 years; as of January 1, 2017.” (opens the source at this quote in a new tab)

Prevalence: share of the advanced population without a targetable alteration

“However, for ∼60% of patients diagnosed with ABC, there is currently no targetable alteration identified; thus second-line therapy options will be limited to further cytotoxic chemotherapy.” (opens the source at this quote in a new tab)

“Patients with BTC have a poor prognosis despite first-line treatment with chemotherapy and immunotherapy, and there is no generally accepted standard of care in later lines of treatment, except for therapies addressing targeted mutations, which is estimated to be approximately 15% to 20% of the patient population.” (opens the source at this quote in a new tab)